Seungbum Kang1, Young-Jung Roh. 1. Department of Ophthalmology and Visual Sciences, College of Medicine, The Catholic University of Korea, Seoul, Korea.
Abstract
PURPOSE: To report 1-year clinical outcomes of intravitreal ranibizumab treatment for choroidal neovascularization (CNV) due to age-related macular degeneration (AMD) and to identify predictive factors that may influence visual acuity (VA) outcomes in Korean patients. METHODS: Sixty patients (64 eyes) with subfoveal CNV were followed up over 12 months after intravitreal injection (0.5 mg) of ranibizumab at baseline and subsequent injections on an as-needed basis. The VA outcomes over 12 months were compared with baseline VA and evaluated across subgroups based on sex, age, baseline VA, CNV size, CNV type, and presence or absence of systemic disease and prior photodynamic therapy. RESULTS: VA improved or remained stable in 46 of 64 eyes (71.9%) at 12 months. Subgroup analysis showed that both baseline VA and CNV size influenced VA outcomes after ranibizumab treatment (P = 0.039, P = 0.042, respectively). However, the patients' sex (P = 0.643), baseline age (P = 0.361), CNV type (P = 0.940), and the presence or absence of systemic disease (P = 0.775) and prior photodynamic therapy (P = 0.890) did not affect VA outcomes. CONCLUSIONS: Intravitreal injections of ranibizumab improve mean VA in patients with subfoveal CNV secondary to AMD, and baseline VA and CNV lesion size were predictive factors of VA outcomes after ranibizumab treatment in Korean patients.
PURPOSE: To report 1-year clinical outcomes of intravitreal ranibizumab treatment for choroidal neovascularization (CNV) due to age-related macular degeneration (AMD) and to identify predictive factors that may influence visual acuity (VA) outcomes in Korean patients. METHODS: Sixty patients (64 eyes) with subfoveal CNV were followed up over 12 months after intravitreal injection (0.5 mg) of ranibizumab at baseline and subsequent injections on an as-needed basis. The VA outcomes over 12 months were compared with baseline VA and evaluated across subgroups based on sex, age, baseline VA, CNV size, CNV type, and presence or absence of systemic disease and prior photodynamic therapy. RESULTS: VA improved or remained stable in 46 of 64 eyes (71.9%) at 12 months. Subgroup analysis showed that both baseline VA and CNV size influenced VA outcomes after ranibizumab treatment (P = 0.039, P = 0.042, respectively). However, the patients' sex (P = 0.643), baseline age (P = 0.361), CNV type (P = 0.940), and the presence or absence of systemic disease (P = 0.775) and prior photodynamic therapy (P = 0.890) did not affect VA outcomes. CONCLUSIONS: Intravitreal injections of ranibizumab improve mean VA in patients with subfoveal CNV secondary to AMD, and baseline VA and CNV lesion size were predictive factors of VA outcomes after ranibizumab treatment in Korean patients.
Authors: David S Boyer; Andrew N Antoszyk; Carl C Awh; Robert B Bhisitkul; Howard Shapiro; Nisha R Acharya Journal: Ophthalmology Date: 2007-02 Impact factor: 12.079
Authors: David M Brown; Peter K Kaiser; Mark Michels; Gisele Soubrane; Jeffrey S Heier; Robert Y Kim; Judy P Sy; Susan Schneider Journal: N Engl J Med Date: 2006-10-05 Impact factor: 91.245
Authors: Evangelos S Gragoudas; Anthony P Adamis; Emmett T Cunningham; Matthew Feinsod; David R Guyer Journal: N Engl J Med Date: 2004-12-30 Impact factor: 91.245
Authors: Keven J Blinder; Shannon Bradley; Neil M Bressler; Susan B Bressler; Guy Donati; Yong Hao; Colin Ma; Ugo Menchini; Joan Miller; Michael J Potter; Constantin Pournaras; Al Reaves; Philip J Rosenfeld; H Andrew Strong; Michael Stur; Xiang Yao Su; Gianni Virgili Journal: Am J Ophthalmol Date: 2003-09 Impact factor: 5.258
Authors: Ziad F Bashshur; Zeina A Haddad; Alexandre Schakal; Rola F Jaafar; Marc Saab; Baha' N Noureddin Journal: Am J Ophthalmol Date: 2007-12-11 Impact factor: 5.258
Authors: Peter K Kaiser; David M Brown; Kang Zhang; Henry L Hudson; Frank G Holz; Howard Shapiro; Susan Schneider; Nisha R Acharya Journal: Am J Ophthalmol Date: 2007-10-22 Impact factor: 5.258
Authors: Carl D Regillo; David M Brown; Prema Abraham; Huibin Yue; Tsontcho Ianchulev; Susan Schneider; Naveed Shams Journal: Am J Ophthalmol Date: 2008-02 Impact factor: 5.258
Authors: A H Ross; P H J Donachie; A Sallam; I M Stratton; Q Mohamed; P H Scanlon; J N Kirkpatrick; R L Johnston Journal: Eye (Lond) Date: 2012-11-23 Impact factor: 3.775
Authors: Shi Zhuan Tan; Augustinus Laude; Peter A Aspinall; Anna M Ambrecht; Archana Vani; Baljean Dhillon Journal: Int Ophthalmol Date: 2013-01-29 Impact factor: 2.031
Authors: Jay Chhablani; Jae Suk Kim; William R Freeman; Igor Kozak; Hai-Yan Wang; Lingyun Cheng Journal: Int J Ophthalmol Date: 2013-02-18 Impact factor: 1.779
Authors: H Nakanishi; A Tsujikawa; Y Yodoi; Y Ojima; A Otani; H Tamura; K Yamashiro; S Ooto; N Yoshimura Journal: Eye (Lond) Date: 2011-01-21 Impact factor: 3.775